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Abstract
Background: HER-2/neu and VEGF expression is correlated with disease behaviors in various cancers. However,
evidence for their expression in colon cancer is rather contradictory both for the protein expression status and
prognostic value. HER-2/neu is found to participate in VEGF regulation, and has known correlation with VEGF
expression in some tumors. In this study, we investigated HER-2/neu and VEGF expression in Chinese colon
patients and explored whether there was any correlation between their expression patterns.
Methods: HER-2/neu and VEGF were investigated immunohistochemically using tumor samples obtained from
317 colon cancer patients with all tumor stages. Correlation of the degree of staining with clinicopathological
parameters and survival was investigated.
Results: Positive expression rates of HER-2/neu and VEGF in colon cancer were 15.5% and 55.5% respectively.
HER-2/neu expression was significantly correlated with tumor size and distant metastases (P < 0.05), but was not
an independent prognostic marker of survival (P > 0.05). Expression of VEGF was significantly correlated with tumor
size, tumor stage, lymph node metastases, and distant metastases (P < 0.05). The 5-year survival rate in patients
with negative and positive VEGF expression was 70.2% and 61.9% respectively; the difference was not statistically
significant (P = 0.146). No correlation between HER-2/neu and VEGF expression was detected (P=0.151).
Conclusions: HER-2/neu and VEGF are not important prognostic markers of colon cancer. The present results do
not support any association between HER2/neu and VEGF expression in this setting.
Background
Colorectal cancer (CRC) is one of the most common
malignancies worldwide and is the fourth leading cause
of cancer-related death in China. Although the develop-
ment of new cytotoxic agents such as oxaliplatin and iri-
notecan and new surgical techniques has improved
prognosis of CRC, once patients develop resistance to
chemotherapeutic regimens no other treatment options
are available. Recently, therapeutic strategies have been
improved by the development and availability of mono-
clonal antibodies. Investigators have recently been evalu-
ating biologic and molecular targets for their possible
roles as prognostic markers and as targets for therapy.
The HER-2/neu oncogene, also known as c-erbB-2,
encodes a transmembrane tyrosine kinase receptor,
homologous to epidermal growth factor receptor
(EGFR), This receptor is involved in the growth and
progression of malignant cells. For instance, overexpres-
sion of the HER-2/neu is detectable in 25%-35% of
breast cancers [1-3]. Treatment of these patients with
trastuzumab (Herceptin), an anti-HER-2/neu monoclo-
nal antibody, has been shown to reduce tumor volume,
magnify the effects of chemotherapy, and increase survi-
val rate in primary and metastatic breast cancer [4,5].
The success of anti-HER-2/neu therapy in breast cancer
has led to evaluations of HER-2/neu expression in mul-
tiple tumors, colon cancer among them, but conflicting
data exist with reports of its expression in CRC ranging
at 0-80% [6-8].
Vascular endothelial growth factor (VEGF)-A,
formerly known as VEGF, is an angiogenic factor that is
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microvessel proliferation (neoangiogenesis). Tumor
angiogenesis contributes to the metastatic process by
promotion of leaking blood vessels for vascular invasion
[9,10]. VEGF expression has been shown to be upregu-
lated in many tumors and to be of prognostic value
[11-13]. Furthermore, treatment with bevacizumab, a
monoclonal antibody against VEGF, in combination
with chemotherapy results in significant improvements
in overall survival and progression-free survival com-
pared with chemotherapy alone [14-16]. In addition,
recently HER-2/neu was found to participate in and be
correlated with VEGF expression [17-20]. However, no
previous studies have clarified their associations in colon
cancer. The purposes of this study were to examine
expression status of HER-2/neu and VEGF in colon can-
cer and to evaluate whether their expression levels are
correlated with each other and with clinicopathological
parameters and prognosis.
Methods
Between January 2000 and December 2005, a total of 317
patients received elective surgery for colon cancer at the
Department of General Surgery of First Clinic Medical
School of YangZhou University. The patients comprised
187 men and 130 women aged 21-86 (mean 57.8) years.
No patient received anticancer treatment prior to sur-
gery. Patients’ clinicopathologic parameters including
sex, age, and tumor differentiation, location, and pTNM
pathological classification according to the International
Union Against Cancer (UICC) were collected.
Immunohistochemistry
Immunohistochemical analysis for HER-2/neu and
VEGF expression was performed on formalin-fixed par-
affin-embedded sections of surgical specimens. The
slides were deparaffinized in xylene and rehydrated in
ethanol solution. Endogenous peroxidase was blocked
with 0.3% H2O2 in methanol for 10 min. The slides
were immersed in 10 mm citric buffer (pH 6.0) with
heating for 15 min for antigen retrieval, then cooled at
room temperature for 20 min and washed with phos-
phate-buffered saline (PBS). Nonspecific binding was
blocked by preincubation with 10% fetal calf serum in
PBS with 0.01% sodium azide then the slides were incu-
bated in a humidifier chamber for 1 h with antibody
against VEGF(titer 1:50; Dako Cytomation, Denmark)
and HER-2/neu HercepTest™ kit (titer 1:100;Dako
Cytomation, Denmark). After washing three times in
PBS, the slides were incubated with the envision-HrP
complex (undiluted; Dako) for 60 min then visualized
with diaminobenzidine and counterstained with hema-
toxylin. For substitute negative controls, the primary
antibody was replaced with PBS. Positive controls
included breast cancer tissue known to exhibit high
levels of marker.
Scoring systems
The slides were assessed by two pathologists with minimal
interobserver variability including resolution of observed
differences by simultaneous reevaluation. HER-2/neu stain-
ing was scored semiquantitatively according to the follow-
ing scoring system approved by the US Food and Drug
Administration (FDA): 0, no immunostaining or membrane
staining in < 10% of the tumor cells; 1+, incomplete mem-
brane staining of > 10% of tumor cells; 2+, weak-to-moder-
ately complete membrane staining of > 10% of tumor cells;
3+, a moderate-to-strongly complete membrane staining
of > 10% of tumor cells. Scores of 0 or 1+ indicated a
tumor negative for HER-2/neu expression, and scores of 2
+ and 3+ were regarded as positive expression of HER-2/
neu.VEGF was graded according to previously established
criteria [21]. A positive result constituted > 10% of cells
stained, and a negative result constituted < 10% of cells
stained. Intensity of staining was graded on a scale of 0 to
3+, with 3+ representing the strongest staining.
Follow-up
Patients underwent continuous follow-up as of January
2011. No patient was lost to follow-up. The median fol-
low-up interval was 68.8 months.
Statistics
The results were analyzed using the statistical software
package SPSS for Windows, version 13 (SPSS, USA).
Association of HER-2/neu and VEGF staining with clini-
copathological parameters was analyzed by c2t e s t .
Overall survival curves were calculated using the
method of Kaplan and Meier, differences between the
curves were analyzed by log-rank test. Statistical signifi-
cance was set at P < 0.05.
Results
Expression of HER-2/neu and VEGF
HER-2/neu expression was positive in 49 of 317 colon
cancer samples (15.5%) and negative in the remaining
268 samples (84.5%), only seven samples were strongly
positive. VEGF expression was positive in 176 of 317
colon cancer samples (55.5%) and negative in the remain-
ing 141 samples (44.5%), 46 samples(14.5%) were 1+,79
(24.9%) were 2+, and 51(16.1%) were 3+. Figure 1 shows
HER-2/neu and VEGF staining patterns in colon cancer.
Association between HER-2/neu and VEGF
HER-2/neu was detectable in 31 of 176 (17.6%) patients
with VEGF-positive expression, in contrast to 18 of 141
(12.8%) patients with VEGF-negative expression
(Table 1); the difference was not statistically significant.
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features
Correlations of HER-2/neu and VEGF in colon cancer
with clinical features are shown in Table 2. HER-2/neu
expression correlated with tumor size and distant metas-
tases (both P < 0.05), but not with other clinicopatholo-
gical features assessed (all P > 0.05). Expression of
VEGF correlated with tumor size, T stage, lymph node
metastases and distant metastases (all P < 0.05). Statisti-
cal evaluation of VEGF expression according to age, sex,
tumor location, differentiation grade, and perineural
invasion revealed no significant difference among these
variables (all P > 0.05).
Survival analysis
All patients underwent follow-up until cancer-related
death or > 5 years after tumor resection. The 5-year
survival of HER-2/neu-positive patients was 63.3%, and
did not differ significantly from that of HER-2/neu-
negative individuals (66.0%; c2 = 0.062, P = 0.804). The
5-year survival for patients with negative and positive
VEGF expression was 70.2% and 61.9% respectively,
with a tendency of shorter survival in the latter versus
former group, although the difference was not statisti-
cally significant (c
2 = 2.114, P = 0.146).
Discussion
HER-2/neu is a proto-oncogene that encodes a trans-
membrane protein with tyrosine kinase activity and is
closely related to but biologically distinct from EGFR.
Amplification and overexpression of the HER-2/neu
gene have been demonstrated in several tumors such as
breast, stomach, lung, and urinary bladder. The fre-
quency of positivity appears to increase with clinical
stage of disease and is associated with a worse prognosis
[22-24]. Although Her-2/neu has been postulated as a
prognostic biological marker for colorectal caner, con-
flicting data exist about the prevalence of HER-2/neu
overexpression in CRC as well as its relationship with
prognosis. We examined 317 colon cancer samples for
the presence of Her-2/neu oncoprotein by immunohis-
tochemistry. In all, 49 samples (15.5%) showed positive
expression of Her-2/neu; only 7 samples were strongly
membrane positive. Similar results were described in
the study of Kavanagh et al.[25] They examined HER-2/
neu protein expression in 132 CRC specimens, and
found HER-2/neu overexpression in 11%, with 2 dis-
playing were strong membranous immunostaining[25].
Our research showed that HER-2/neu expression was
related with tumor size and distant metastases, suggest-
ing that this protein may participate in tumor growth
and distant metastasis although it was not a significant
index of survival.
Previous reports that have demonstrated associations
between HER-2/neu protein expression and more
aggressive colorectal tumors. Demirbas et al [26]
reported an association between HER-2/neu overexpres-
sion and tumor size (> 5 cm), differentiation grade, and
vascular and lymphatic invasion. Besides, their patients
with HER-2/neu protein-positive expression had shorter
disease-free survival and overall survival compared with
those who were negative. They suggested that overex-
pression of HER-2/neu protein played an important role
in the progression of CRC and was considered an
independent prognostic indicator. On the other hand,
Jesus et al [27] reported that the HER-2/neu expression
was not correlated with sex, age, tumor differentiation,
localization of the primary tumor and overall survival.
They indicated that HER-2/neu expression was unlikely
to play a major role in the therapeutic management of
colorectal cancer.
Figure 1 Immunohistochemical staining for HER-2/neu and VEGF (original magnification, × 200). (a) Strong cytoplasmic stain in > 10% of
tumor cells. (b) VEGF stained in > 10% of tumor cells. (c) No expression of VEGF and c-erbB-2 in colon cancer.
Table 1 Relation between HER-2/neu and VEGF
expression
VEGF expression HER-2/neu expression Total P-value
a
Positive Negative
Positive 31 145 176
Negative 18 123 141 0.151
a Pearson c
2 test
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between studies to date. The most likely reason for the
divergent findings is the different scoring systems-for
example, Uner et al[28] judged only membrane staining
in > 20% of tumor cells to be positive. The inclusion of
cytoplasmic positivity in some papers may also be
responsible for the conflicting results, because there is
relatively high percent of positive cytoplasmic staining
in CRC. Sensitivity of the antibodies used also makes
the comparison between studies very challenging; the
HercepTest™ kit (Dako) is the only antibody
recommended by the FDA for HER-2/neu examination.
Different antibodies may lead to different results, Park
et al [23] reported a 47% protein expression rate using a
polyclonal antibody (Zymed, South San Francisco, USA)
and correlated overexpression with a higher incidence of
postoperative recurrence. Conversely, Schuell et al [29]
demonstrated an overexpression rate of 4% that was not
correlated with survival using the validated HercepT-
est™ kit. Moreover, immunohistochemistry is a semi-
quantitative method and may easily be influenced by
researchers’ subjective perception. In addition, ethnic
diversity of patients should be taken into account.
Ghaffarzadegan et al[30] examined 69 Iranian colorectal
samples and showed HER-2/neu staining in a high per-
cent of cases with 65.9% showing cytoplasmic staining
and 34.1% membranous-cytoplasmic staining and more
prominent membranous staining in higher stages and
grades. Kavanagh et al[25] detected that HER-2/neu
protein was overexpressed in only 11% of Irish CRC
patients, and found no correlation with tumor grade,
Dukes’ stage, time to recurrence and 5-year survival.
Angiogenesis represents an important event in the
process of tumor invasion and metastases, and it is well
established that VEGF is one of the most important
molecules promoting endothelial cell migration,
proliferation, and differentiation [31,32]. In our study,
VEGF expression was noted in more than half of colon
cancers (55.5%). Both the incidence and proportion of
VEGF expression increased with the progression of col-
orectal carcinogenesis classified by depth of tumor inva-
sion, presence of lymph node metastases and distant
Table 2 Clinicopathological variables and their correlation with immunohistochemical expression of HER-2/neu and
VEGF
Variable Patients HER-2/neu P-value
a VEGF P-value
a
Positive Negativ Positive Negative
Sex 0.553 0.438
Male 187 29 158 105 82
Female 130 20 110 71 59
Age 0.525 0.817
≤60 195 28 167 107 88
> 60 122 21 101 69 53
Tumor size (cm) 0.004 0.000
< 5 cm 211 23 183 95 111
≥ 5 cm 106 26 85 81 30
Differentiation grade 0.193 0.451
Well 90 10 80 55 35
Moderate 152 23 129 81 71
Poor 75 16 59 40 35
T stage 0.166 0.177
T1~T2 97 11 86 48 49
T3~T4 220 38 182 128 92
Lymph node status 0.460 0.119
Negative 167 25 142 87 80
Positive 150 24 126 89 61
Distant metastasis 0.010
b 0.017
M0 291 40 251 156 135
M1 26 9 17 20 6
Perineural invasion 0.127
b 0.232
Negative 299 44 255 168 131
Positive 18 5 13 8 10
a Pearson c
2 test
b Adjusted c
2 test
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Takahashi et al[33] and Kang et al[34]. Patients with
positive VEGF expression had a tendency of shorter
overall survival, although the difference versus negative
patients was nonsignificant, suggesting that VEGF-
positive phenotype in colon cancer may not provide
additional prognostic value. This result is consistent
with that of Lee et al [35]. In contrast, Kang et al [34]
found that immunohistochemical expression of VEGF
was an independent prognostic factor for CRC patients.
VEGF is one of the most potent inducers of angiogen-
esis, whereas HER-2/neu has been implicated in the
regulation of VEGF. In human breast cancer, overexpres-
sion of HER-2/neu is correlated with increased VEGF
expression [17,19]. Klos et al [20] demonstrated that
HER-2/neu activation led to translational upregulation of
VEGF and increased angiogenesis through ERK, PI3K/
Akt, mTOR, and p70S6K. Petit et al [36] observed that
neutralizing antibodies (trastuzumab) against HER-2/neu-
positive breast cancer cell lines downregulated expression
of VEGF by twofold. On the other hand, trastuzumab
decreased tumor VEGF expression through the PI3K/Akt
pathway in HER-2/neu-positive cancer cells[11,37-39],
and could also increase anti-angiogenic factor and inhibit
additional pro-angiogenic factors such as transforming
growth factor-a, angiopoietin-1, plasminogen-activator
inhibitor-1, and interleukin(IL)-8 [11,37]. Therefore,
trastuzumab could exert synergistic interaction with anti-
VEGF monoclonal antibody to suppress tumor angiogen-
esis by modulation of multiple angiogenic factors.
Human breast cancers overexpressing HER-2/neu may
be ideal targets for dual therapy with agents that inhibit
VEGF and HER-2/neu. Conversely, no correlation was
found between VEGF and c-erbB-2 in squamous cell car-
cinoma of the head and neck [40], and there is little
research on correlation of VEGF and HER-2/neu in
colon cancer.
The present study showed that VEGF was higher in
HER-2/neu-positive tumor specimens than in those that
were negative. Meanwhile, HER-2/neu expression was
greater in VEGF-positive tumor than in VEGF-negative
tumor, although the difference was not statistically sig-
nificant. These findings suggest that there is no apparent
correlation between HER-2/neu and VEGF expression in
colon cancer. Our results are similar to those of Ochs et
al [41] who reported that association was not supported
between HER-2/neu and VEGF expression in stage II
colon cancer. In breast cancer, angiogenesis could be
r e g u l a t e db yH E R - 2p a t h w a ye v e ni nt h ea b s e n c eo f
HER-2/neu overexpression,t a r g e t i n gd o w n s t r e a m
targets of HER-2, particulary those leading to VEGF
transcription and angiogenesis, could likely produce
additional antitumor effects [42]. However, whether this
approach could be useful against colon cancer neovascu-
larization deserves further research.
Conclusions
Our study aimed at evaluating the expression of
c-erbB-2 and VEGF in colon cancer by immunohisto-
chemical methods. We found HER-2/neu and VEGF is
not important prognostic markers of colon cancer, and
our results do not support an association between
HER2/neu and VEGF expression.
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